Pharmaceuticals

RevOpsis and Kemwell Biopharma Announce Collaboration to Accelerate Manufacturing of Novel Multispecific Biologics

bexib
By bexib 0 Min Read

The CDMO’s facilities will be used to accelerate production for the treatment of nAMD.

You Might Also Like

FDA grants breakthrough therapy designation to GSK’s GSK5764227 for relapsed or refractory extensive-stage small cell lung cancer

GOSH and Oliver Patch partner with Innovative Trials to conduct cancer research

The Future of Biosimilars: Q&A with Matt Erich

FDA grants priority review to Novartis’ Sembrix for newly diagnosed patients with chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia

Health In Tech Announces New Partnership to Expand Health Insurance Options for Employers in Southern Ohio

Share This Article
Previous Article Link June 18, 2024 | Naked Capitalism
Next Article Joshua Howard’s Driftwood Wreath – How to Make It:
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Fifth Third expands branch network and doubles technology capabilities
Banking
KeyBank increases technology spending by 10% in 2025
Banking
Trump’s fintech appointees could influence regulation
Banking
10 books for better communication
Retail & E-commerce